1. Share Prices

  2. Hvivo PLC (HVO)

14.00p-0.75 (-5.08%)28 Mar 2025, 16:35
Find out how to deal online from £1.50 in a SIPP, ISA or Dealing account.AJ Bell logo
Jump to:

Hvivo PLC Fundamentals

Company NameHvivo PLCLast Updated2025-03-28
IndustryBiotechnologySectorHealthcare
Shares in Issue686.812 mMarket Cap£96.15 m
PE Ratio5.53Dividend per Share0
Dividend Yield1.43Dividend Cover0
EPS£0.02EPS Growth (%)2.28
PEG0DPS Growth (%)0
Debt Ratio0.1484Debt Equity Ratio0.3033
Asset Equity Ratio2.2812Cash Equity Ratio0.9644
Quick Ratio1.5586Current Ratio1.61
Price To Book Value2.5000ROCE0

Hvivo PLC Dividends

TypeEx-DatePay DateCurrencyNet DividendYear Total
Prelim2024-04-182024-05-20GBP0.0020

Hvivo PLC Company Financials

Assets20232022
Tangible Assets£20.04 m£3.12 m
Intangible Assets£5.67 m£6.02 m
Investments00
Total Fixed Assets£31.22 m£9.15 m
Stocks£426,000.00£499,000.00
Debtors£13.20 m£12.30 m
Cash & Equivalents£36.97 m£28.44 m
Other Assets£5.52 m0
Total Assets£83.23 m£51.38 m
Liabilities20232022
Creditors within 1 year£35.18 m£29.77 m
Creditors after 1 year£13.72 m£1.40 m
Other Liabilities00
Total Liabilities£48.90 m£31.16 m
Net assets£34.33 m£20.22 m
Equity20232022
Called up share capital£680,000.00£671,000.00
Share Premium£516,000.00£4,000.00
Profit / Loss£11.15 m-£365,000.00
Other Equity£34.33 m£20.22 m
Preference & Minorities00
Total Capital Employed£34.33 m£20.22 m
Ratios20232022
Debt Ratio£0.26£0.04
Debt-to-Equity£0.35£0.04
Assets / Equity2.28122.2812
Cash / Equity0.96440.9644
EPS£0.02£0.01
Cash Flow20232022
Cash from operating activities£17.24 m£15.98 m
Cashflow before financing£13.72 m£14.15 m
Increase in Cash£8.54 m£12.79 m
Income20232022
Turnover£56.04 m£48.48 m
Cost of sales00
Gross Profit00
Operating Profit£10.10 m£6.02 m
Pre-Tax profit£11.15 m-£365,000.00

Hvivo PLC Company Background

SectorHealthcare
ActivitieshVIVO PLC is a European-focused, rare, and orphan drug consulting services platform. The principal activity of the Group is that of a rapidly growing specialist CRO pharmaceutical services company, which involves the testing of vaccines and antivirals using human-challenge clinical trials. The group is also engaged in Venn Life Sciences' Clinical Research Division, providing a suite of consulting and clinical trial services to pharmaceutical, biotechnology, and medical device organizations.
Latest Interim Date10 Sep 2024
Latest Fiscal Year End Date9 Apr 2024

Hvivo PLC Directors

AppointedNamePosition
2020-01-20Mr. Michael P Ryan Non-Executive Director,Senior Independent Director
2013-06-18Mr. Adam ReynoldsNon-Executive Director
2014-04-14Mr. Paul Andrew Peter FoulgerExecutive Director,Finance Director and Company Secretary
2016-01-08Mr. David Eric EvansNon-Executive Director,Chairman
2020-07-06Mr. Anthony Francis Richardson Executive Director,Corporate Development Director
2019-06-13Mr. Paul Francis Kennedy Non-Executive Director
2018-12-11Mr. Allan Leigh Wood Executive Director,Chairman
2024-07-23Mr. Cathal Martin FrielNon-Executive Director,Chairman
2019-06-11Ms. Mary Blake Sheahan Non-Executive Director
2017-08-16Ms. Gracielle Anna Maria Beijerbacht-SchutjensExecutive Director,Chief Operating Officer
2018-03-21Mr. Jonathan David HartshornExecutive Director,Chief Financial Officer
2020-05-04Mr. Mark Robert WarneNon-Executive Director
2017-04-06Mr. Kees GroenExecutive Director
2020-01-20Dr. Christian Bernard MillaExecutive Director,Chief Operating Officer
2024-04-15Professor Brendan BuckleyNon-Executive Director
2020-01-20Dr. Maurice Treacy Executive Director
2025-03-13Mr. Yamin Mohammed KhanExecutive Director,Chief Executive Officer
2024-02-15Mr. Stephen PinkertonExecutive Director,Chief Financial Officer

Hvivo PLC Contact Details

Company NamehVIVO PLC
Address1 Berkeley Street, London, W1J 8DJ
Telephone+353 15373269
Websitehttps://www.hvivo.com

Hvivo PLC Advisors

Nominated AdviserCenkos Securities
Phone+44 2073978900
StockbrokerCenkos Securities
Phone+44 2073978900
StockbrokerHybridan LLP
Phone+44 203764 2341
Fax+44 2076001586
BankUlster Bank Group
AuditorJeffreys Henry LLP
Phone+44 2073092222
Fax+44 2073092309
Financial PR AdviserWalbrook PR
Phone+44 2079338780
Fax+44 2079338781
RegistrarS.L.C Registrars Ltd
Phone+44 1903706150
SolicitorBPE Solicitors LLP
Phone+44 1242224433
Fax+44 1242574285

Most Read

Receive our
daily news email

Subscribe to the latest investing news by entering your email address below

You can opt out at any time.

For five days a week you will get

  • The latest company news
  • Insight into investment trends
  • Round-up of director's buys and sells
  • Articles from Shares magazine
Sharesmagazine cover

Plus more useful investment content and occasional promotional offers.

Shares Magazine Latest Issue Cover
Latest Issue:
27 Mar 2025Subscribe now

Market Overview

UK 350 Risers and Fallers

Risers

CompanyPrice% Chg
Sse PLC1,606.003.85
Spire Healthcare Group PLC178.603.84
British Land Company PLC374.403.43
B&M European Value Retail S.A.269.903.37
Supermarket Income Reit PLC77.503.20
National Grid PLC1,009.502.86

Fallers

CompanyPrice% Chg
Close Brothers Group PLC299.80-9.37
Trustpilot Group PLC233.50-6.79
Wizz Air Holdings PLC1,575.00-5.41
Aston Martin Lagonda Global Holdings PLC65.25-5.02
Wh Smith PLC1,039.00-4.68
Melrose Industries PLC492.70-4.63
Risers/fallers data from previous trading day.